We are live on ! Find out more
INSM icon

Insmed

569 hedge funds and large institutions have $30.6B invested in Insmed in 2025 Q3 according to their latest regulatory filings, with 128 funds opening new positions, 195 increasing their positions, 197 reducing their positions, and 70 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 128 | Existing positions closed: 70

12% more capital inflows, than outflows

Capital inflows: $4.2B | Capital outflows: $3.77B

10% more funds holding

Funds holding: 517 → 569 (+52)

1.2% more ownership

Funds ownership: 99.52% → 100.72% (+1.2%)

1% less repeat investments, than reductions

Existing positions increased: 195 | Existing positions reduced: 197

7% less call options, than puts

Call options by funds: $610M | Put options by funds: $657M

27% less funds holding in top 10

Funds holding in top 10: 33 → 24 (-9)

Holders
569
Holders Change
+52
Holders Change %
+10.06%
% of All Funds
7.43%
Holding in Top 10
24
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-27.27%
% of All Funds
0.31%
New
128
Increased
195
Reduced
197
Closed
70
Calls
$610​M
Puts
$657​M
Net Calls
-⁠$47.7​M
Net Calls Change
+$8.54​M

INSM Hedge Fund Activity: Q3 2025 in Review

569 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q3 2025, worth a combined $30.6B — up 45% from $21.1B a quarter earlier.

Buyers outnumbered sellers: 128 funds opened new INSM positions and 70 closed out — a net gain of 58 holders — while 195 added to existing stakes and 197 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $908M. The largest seller was T. Rowe Price Associates, cutting an estimated $527M.

  • 569 institutional investors held Insmed (INSM) as of Q3 2025, up from 517 in Q2 2025.
  • Funds reported $30.6B of Insmed stock for Q3 2025, up 45% quarter-over-quarter.
  • 128 funds opened new Insmed positions in Q3 2025 and 70 closed out, a net change of +58 holders.
  • The largest Insmed buyer in Q3 2025 was JP Morgan Chase, an estimated $908M added.
  • The largest Insmed seller in Q3 2025 was T. Rowe Price Associates, an estimated $527M sold.

Based on aggregated 13F filings for Q3 2025.